ZA200410160B - Use of compounds that are effective as selective opiate receptor modulators - Google Patents

Use of compounds that are effective as selective opiate receptor modulators Download PDF

Info

Publication number
ZA200410160B
ZA200410160B ZA2004/10160A ZA200410160A ZA200410160B ZA 200410160 B ZA200410160 B ZA 200410160B ZA 2004/10160 A ZA2004/10160 A ZA 2004/10160A ZA 200410160 A ZA200410160 A ZA 200410160A ZA 200410160 B ZA200410160 B ZA 200410160B
Authority
ZA
South Africa
Prior art keywords
effective
compounds
opiate receptor
treatment
composition
Prior art date
Application number
ZA2004/10160A
Other languages
English (en)
Inventor
Gottschlich Rudolf
Jacob Jutta
Weber Frank
Barber Andrew
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Publication of ZA200410160B publication Critical patent/ZA200410160B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2004/10160A 2002-05-17 2004-12-15 Use of compounds that are effective as selective opiate receptor modulators ZA200410160B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011047 2002-05-17
PCT/EP2003/004428 WO2003097051A2 (en) 2002-05-17 2003-04-28 Use of compounds that are effective as selective opiate receptor modulators

Publications (1)

Publication Number Publication Date
ZA200410160B true ZA200410160B (en) 2005-12-28

Family

ID=29433078

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/10160A ZA200410160B (en) 2002-05-17 2004-12-15 Use of compounds that are effective as selective opiate receptor modulators

Country Status (20)

Country Link
US (1) US20050176746A1 (https=)
EP (2) EP1505974B1 (https=)
JP (1) JP2005531557A (https=)
KR (1) KR101108014B1 (https=)
CN (2) CN101310723A (https=)
AR (1) AR040028A1 (https=)
AT (1) ATE429226T1 (https=)
AU (1) AU2003242527B2 (https=)
BR (1) BR0309969A (https=)
CA (1) CA2486000A1 (https=)
DE (1) DE60327315D1 (https=)
DK (1) DK1505974T3 (https=)
ES (1) ES2325782T3 (https=)
MX (1) MXPA04011333A (https=)
PE (1) PE20040455A1 (https=)
PL (1) PL371596A1 (https=)
RU (1) RU2336871C2 (https=)
TW (1) TWI314053B (https=)
WO (1) WO2003097051A2 (https=)
ZA (1) ZA200410160B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
RU2413512C1 (ru) * 2009-07-29 2011-03-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Средство, обладающее каппа-опиоидной агонистической активностью
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина
US20160250277A1 (en) * 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4215231C1 (en) 1992-05-09 1993-05-13 Dornier Luftfahrt Gmbh, 8031 Wessling, De Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
JPH11343244A (ja) * 1998-03-30 1999-12-14 Taisho Pharmaceut Co Ltd 経口用組成物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
WO2001097753A2 (en) * 2000-06-19 2001-12-27 Eisai Co. Ltd. Novel methods using pyridine derivatives
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
DE10030893A1 (de) * 2000-06-23 2002-01-03 Henkel Kgaa Paraaminophenol-Derivate und deren Verwendung
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US6780891B2 (en) * 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof

Also Published As

Publication number Publication date
DE60327315D1 (de) 2009-06-04
DK1505974T3 (da) 2009-08-17
KR20050010807A (ko) 2005-01-28
TWI314053B (en) 2009-09-01
AR040028A1 (es) 2005-03-09
RU2336871C2 (ru) 2008-10-27
ES2325782T3 (es) 2009-09-17
US20050176746A1 (en) 2005-08-11
AU2003242527A1 (en) 2003-12-02
EP1505974A2 (en) 2005-02-16
HK1079451A1 (zh) 2006-04-07
CN100411618C (zh) 2008-08-20
KR101108014B1 (ko) 2012-01-25
BR0309969A (pt) 2005-04-26
TW200307541A (en) 2003-12-16
WO2003097051A3 (en) 2004-12-09
ATE429226T1 (de) 2009-05-15
PL371596A1 (en) 2005-06-27
MXPA04011333A (es) 2005-02-14
AU2003242527B2 (en) 2008-10-23
RU2004137091A (ru) 2005-09-10
WO2003097051A2 (en) 2003-11-27
CA2486000A1 (en) 2003-11-27
CN1655784A (zh) 2005-08-17
PE20040455A1 (es) 2004-08-07
CN101310723A (zh) 2008-11-26
EP2074997A1 (en) 2009-07-01
JP2005531557A (ja) 2005-10-20
EP1505974B1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
AU2003242527B2 (en) Use of compounds that are effective as selective opiate receptor modulators
JP2584899B2 (ja) 体重減量医薬組成物
US20080255093A1 (en) Compositions and methods for treating obesity and related disorders
IL293907A (en) Treatment of amyotrophic lateral sclerosis and related disorders
JPS61277620A (ja) 排尿困難治療剤
EP0244080A2 (en) Medicament for the treatment of obesity
JP2022524398A (ja) 化合物の製剤およびそれらの使用
US12201610B2 (en) Compositions comprising aticaprant
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
AU2273899A (en) Therapeutic agents
WO2006022420A1 (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2005049043A1 (en) Combination therapy comprising metformin and anticonvulsant agents
JP2025083453A (ja) Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法
TW200529847A (en) Pharmaceutical composition for use in the treatment of chronic fatigue syndrome or fibromyalgia or associated functional symptoms of fibromyalgia
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
KR20240006600A (ko) 투약 요법
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
AU2015360620A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
HK1079451B (en) Use of compounds that are effective as selective opiate receptor modulators
Kale et al. Bioequivalence study of Trazodone: single oral dose under fasting condition in healthy human subjects
WO2020144647A1 (en) Pharmaceutical composition comprising apalutamide dispersed in apple sauce
TO PREVENT RECURRENCE1, 2
NZ614725A (en) Methods and compositions for treating depression using cyclobenzaprine
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine
WO2007079317A2 (en) Use of sedative hypnotics for treating obesity or maintaining weight loss